CytoSorbents to Exhibit at the ISICEM 2013 Critical Care Conference

     CytoSorbents to Exhibit at the ISICEM 2013 Critical Care Conference

PR Newswire

MONMOUTH JUNCTION, N.J., March 13, 2013

MONMOUTH JUNCTION, N.J., March 13, 2013 /PRNewswire/ --CytoSorbents
Corporation (OTCBB: CTSO), a critical care focused company using blood
purification to treat life-threatening illnesses, announced that it will
exhibit its European Union approved CytoSorb® cytokine reduction technology at
the 33^rd International Symposium on Intensive Care and Emergency Medicine
(ISICEM) in Brussels, Belgium from March 19-22, 2013. In addition, Dr. Dirk
Schadler, from the University Hospital, Universitatsklinikum
Schleswig-Holstein, at Kiel University, Kiel, Germany, was selected to present
a poster (#P062) at the conference entitled, "A multicenter randomized
controlled study of an extracorporeal cytokine hemoadsorption device in septic
patients." Finally, CytoSorbents will also host an evening that will bring
together current and potential customers to talk about critical care medicine
and to share real world experiences using CytoSorb®.

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, "We are
pleased at the growing recognition and usage of CytoSorb® by leading experts
in the field of critical care medicine in many different applications. We have
already seen exciting cases in such areas as sepsis, burn injury, trauma, lung
injury, cardiac surgery, liver failure, pancreatitis, influenza, and other
indications. Users have confirmed the simplicity and ease of use of the
CytoSorb® therapy. As we expand our commercialization efforts, we look
forward to beginning a number of investigator-initiated studies this year in
many different areas that may help drive future adoption and awareness for our
technologies."

About ISICEM
The International Symposium on Intensive Care and Emergency Medicine is
organized by the Departments of Intensive Care and Emergency Medicine of
Erasme University Hospital, Universite Libre de Bruxelles, in association with
the Belgian Society of Intensive Care and Emergency Medicine. This annual
conference was started in 1980 and has become established as one of the
largest in its field, now attracting more than 6,000 participants from
countries worldwide. The objectives of this four-day symposium are to provide
participants with an up-to-date review of the most recent, clinically
relevant, developments in research, therapy, and management of the critically
ill. The meeting is open to all physicians, nurses, and other health
professionals with an interest in critical care or emergency medicine.

About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused therapeutic device company
using blood purification to treat life-threatening illnesses commonly seen in
the intensive care unit such as sepsis and infection, influenza, severe lung
injury, trauma, burn injury, and pancreatitis. Its purification technology is
based upon biocompatible, highly porous polymer beads that can efficiently
remove toxic substances from blood and other bodily fluids. The Company's
flagship product CytoSorb^®, a first-in-class extracorporeal cytokine filter
compatible with standard hemodialysis machines, has achieved European Union CE
Mark regulatory approval and is now being commercialized in Europe. The goal
of the CytoSorb^® cytokine filter is to prevent or treat multiple organ
failure, the leading cause of death in the intensive care unit, by reducing
the excessive production of cytokines, or "cytokine storm", that could
otherwise lead to deadly inflammation, organ injury, and death. Organ failure
represents one of the most serious unmet medical needs in modern medicine,
claiming millions of lives around the world, at a cost of tens of billions of
dollars, each year. By actively addressing one of the most important
underlying causes of organ failure, CytoSorb^® represents a potentially
revolutionary advance in the treatment of critical illnesses.

CytoSorbents has been awarded $5 million in contracts from both DARPA and the
US Army, and continues to invest significantly in its research and development
pipeline. One of its most advanced products under development is HemoDefend,
a blood purification technology platform for the blood transfusion industry
intended to reduce transfusion reactions and improve the safety of "old" blood
by removing many substances, such as antibodies, free hemoglobin and
inflammatory mediators that can cause potentially serious and sometimes fatal
transfusion reactions.

CytoSorb^® and HemoDefend are just two of a number of different polymers the
Company has developed for various medical applications, including improved
dialysis, reduction of post-surgical complications in cardiac surgery,
treatment of inflammatory and autoimmune disorders, radio-imaging contrast
removal in imaging and interventional radiology procedures, and the treatment
of rhabdomyolysis, drug overdose, and others. Additional information is
available for download on the Company's website: http://www.cytosorbents.com.

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. CytoSorbents Corporation
and CytoSorbents, Inc believe that its primary risk factors include, but are
not limited to: obtaining government approvals including required FDA and
additional CE Mark approvals; ability to successfully develop commercial
operations; dependence on key personnel; acceptance of the Company's medical
devices in the marketplace; the outcome of potential litigation; compliance
with governmental regulations; reliance on research and testing facilities of
various universities and institutions; the ability to obtain adequate and
timely financing in the future when needed; product liability risks; limited
manufacturing experience; limited marketing, sales and distribution
experience; market acceptance of the Company's products; competition;
unexpected changes in technologies and technological advances; and other
factors detailed in the Company's Form 10-K filed with the SEC on March 31,
2012, which is available at http://www.sec.gov.

Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
pchan@cytosorbents.com

Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222
asheinwald@allianceadvisors.net

Valter Pinto
(914) 669-0222 x201
valter@allianceadvisors.net

SOURCE CytoSorbents Corporation

Website: http://www.cytosorbents.com
 
Press spacebar to pause and continue. Press esc to stop.